Erasmus Bachus

BioPharmaceuticals R&D
Goeteborg, O, Sweden

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 43 publications

Impact of cerebral oxygen saturation on mortality and rehospitalisation in patients with heart failure and the role of physical activity as a modifying factor: the HARVEST-Malmö Study.

Impact of cerebral oxygen saturation on mortality and rehospitalisation in patients with heart failure and the role of physical activity as a modifying factor: the HARVEST-Malmö Study.

Journal: Heart (British Cardiac Society)

Published: May 21, 2025

EuroQol 5-Dimension Questionnaire in Heart Failure With Reduced, Mildly Reduced, and Preserved Ejection Fraction: A Patient-Level Analysis of DAPA-HF and DELIVER.

EuroQol 5-Dimension Questionnaire in Heart Failure With Reduced, Mildly Reduced, and Preserved Ejection Fraction: A Patient-Level Analysis of DAPA-HF and DELIVER.

Journal: JACC. Heart failure

Published: September 11, 2024

Proteomic biomarkers and pathway analysis for progression to heart failure in three epidemiological representative cohorts.

Proteomic biomarkers and pathway analysis for progression to heart failure in three epidemiological representative cohorts.

Journal: European journal of heart failure

Published: July 02, 2024

Prognostic Models for Mortality and Morbidity in Heart Failure With Preserved Ejection Fraction.

Prognostic Models for Mortality and Morbidity in Heart Failure With Preserved Ejection Fraction.

Journal: JAMA cardiology

Published: March 27, 2024

Effects of dapagliflozin according to QRS duration across the spectrum of left ventricular ejection fraction: An analysis of DAPA-HF and DELIVER.

Effects of dapagliflozin according to QRS duration across the spectrum of left ventricular ejection fraction: An analysis of DAPA-HF and DELIVER.

Journal: European journal of heart failure

Published: February 02, 2024

Dapagliflozin and quality of life measured using the EuroQol 5-dimension questionnaire in patients with heart failure with reduced and mildly reduced/preserved ejection fraction.

Dapagliflozin and quality of life measured using the EuroQol 5-dimension questionnaire in patients with heart failure with reduced and mildly reduced/preserved ejection fraction.

Journal: European journal of heart failure

Published: January 29, 2024

Dapagliflozin and Timing of Prior Heart Failure Hospitalization: A Patient-Level Meta-Analysis of DAPA-HF and DELIVER.

Dapagliflozin and Timing of Prior Heart Failure Hospitalization: A Patient-Level Meta-Analysis of DAPA-HF and DELIVER.

Journal: JACC. Heart failure

Published: December 18, 2023

Efficacy of Dapagliflozin According to Heart Rate: A Patient-Level Pooled Analysis of DAPA-HF and DELIVER.

Efficacy of Dapagliflozin According to Heart Rate: A Patient-Level Pooled Analysis of DAPA-HF and DELIVER.

Journal: Circulation. Heart failure

Published: October 27, 2023

Cost-effectiveness of dapagliflozin for patients with heart failure across the spectrum of ejection fraction: A pooled analysis of DAPA-HF and DELIVER data.

Cost-effectiveness of dapagliflozin for patients with heart failure across the spectrum of ejection fraction: A pooled analysis of DAPA-HF and DELIVER data.

Journal: European journal of heart failure

Published: October 13, 2023

Heart failure, chronic obstructive pulmonary disease and efficacy and safety of dapagliflozin in heart failure with mildly reduced or preserved ejection fraction: Insights from DELIVER.

Heart failure, chronic obstructive pulmonary disease and efficacy and safety of dapagliflozin in heart failure with mildly reduced or preserved ejection fraction: Insights from DELIVER.

Journal: European journal of heart failure

Published: July 15, 2023

Galectin-4 is associated with diabetes and obesity in a heart failure population.

Galectin-4 is associated with diabetes and obesity in a heart failure population.

Journal: Scientific reports

Published: July 13, 2023

Efficacy of Dapagliflozin According to Geographic Location of Patients With Heart Failure.

Efficacy of Dapagliflozin According to Geographic Location of Patients With Heart Failure.

Journal: Journal of the American College of Cardiology

Published: March 21, 2023

Showing 1-12 of 43

Last Updated: 09/26/2026